secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001564590-22-036614
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q3 revenue $25.7M (+378% YoY); 2022 guidance raised to $80-85M
--------------------------------------------------------------------------

- Net revenue $25.7M including $1.4M favorable adjustment; ex-adjustment $24.3M (+349% YoY).
- Full-year 2022 revenue guidance raised to $80-85M (ex-adjustment) vs prior $67-75M.
- Net loss narrowed to $7.4M from $13.0M in Q3 2021; cash and equivalents $204.5M.
- National OCS Program (NOP) drove ~90% of US revenue; public offering netted ~$140M.
- Gross margin 71% vs 70% a year ago; operating expenses $23.7M, up from $15.5M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000156459022036614/0001564590-22-036614-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000156459022036614/tmdx-8k_20221103.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-036614

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer